Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

par Po-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Yu-Chen Wu, Ko-Jiunn Liu, Gee-Chen Chang
Publié 2021

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

par Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Publié 2021

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

par Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Publié 2021

Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.

par Kuan-Chung Hsiao, Neng-Yao Shih, Hsun-Lang Fang, Tze-Sing Huang, Ching-Chuan Kuo, Pei-Yi Chu, Yi-Mei Hung, Shao-Wen Chou, Yi-Yuan Yang, Gee-Chen Chang, Ko-Jiunn Liu
Publié 2013

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.

par Jeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, Chung-Yu Chen, Cheng-Yu Chang, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Chih-Wei Wu, Cheng-Ta Yang, Yuh-Min Chen, Gee-Chen Chang
Publié 2014